CN116211860A - Application of CK2 inhibitor CX4945 in preparation of medicines for preventing immune cell depletion in tumor treatment, inhibitor and combination - Google Patents
Application of CK2 inhibitor CX4945 in preparation of medicines for preventing immune cell depletion in tumor treatment, inhibitor and combination Download PDFInfo
- Publication number
- CN116211860A CN116211860A CN202310520332.1A CN202310520332A CN116211860A CN 116211860 A CN116211860 A CN 116211860A CN 202310520332 A CN202310520332 A CN 202310520332A CN 116211860 A CN116211860 A CN 116211860A
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- tumor
- cells
- medicines
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 229940122360 Casein kinase 2 inhibitor Drugs 0.000 title claims abstract description 12
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 12
- 239000003112 inhibitor Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- 229940079593 drug Drugs 0.000 title abstract description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 8
- 238000009169 immunotherapy Methods 0.000 abstract description 5
- 238000002648 combination therapy Methods 0.000 abstract description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 abstract description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 28
- 230000003915 cell function Effects 0.000 description 7
- 238000003501 co-culture Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 102000052052 Casein Kinase II Human genes 0.000 description 4
- 108010010919 Casein Kinase II Proteins 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 102000043139 CK2 family Human genes 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101150063370 Gzmb gene Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940126530 T cell activator Drugs 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310520332.1A CN116211860B (en) | 2023-05-10 | 2023-05-10 | Application of CK2 inhibitor CX4945 in preparation of medicines for preventing immune cell depletion in tumor treatment, inhibitor and combination |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310520332.1A CN116211860B (en) | 2023-05-10 | 2023-05-10 | Application of CK2 inhibitor CX4945 in preparation of medicines for preventing immune cell depletion in tumor treatment, inhibitor and combination |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116211860A true CN116211860A (en) | 2023-06-06 |
CN116211860B CN116211860B (en) | 2023-08-22 |
Family
ID=86571679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310520332.1A Active CN116211860B (en) | 2023-05-10 | 2023-05-10 | Application of CK2 inhibitor CX4945 in preparation of medicines for preventing immune cell depletion in tumor treatment, inhibitor and combination |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116211860B (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105560239A (en) * | 2015-12-30 | 2016-05-11 | 耿炜 | Use of CX4945 for preparation of drug having reversal effect on gastric cancer cisplatin-resistant radiation tolerance |
WO2017070137A1 (en) * | 2015-10-20 | 2017-04-27 | Bristol-Myers Squibb Company | Combination of ck2 inhibitors and immune checkpoint modulators for cancer treatment |
TW201737940A (en) * | 2016-04-08 | 2017-11-01 | 基利科學股份有限公司 | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
US20200123153A1 (en) * | 2018-10-19 | 2020-04-23 | Senhwa Biosciences, Inc. | Combinations for immune-modulation in cancer treatment |
CN112274642A (en) * | 2020-10-15 | 2021-01-29 | 北京大学人民医院 | Application of CK2 inhibitor in preparation of medicine for treating rheumatoid arthritis |
CN112789292A (en) * | 2018-07-31 | 2021-05-11 | 皮里斯制药有限公司 | Novel fusion proteins specific for CD137 and PD-L1 |
CN114617878A (en) * | 2022-05-16 | 2022-06-14 | 深圳大学 | Application of CK2 inhibitor in preparation of anti-aging drugs |
RU2021114145A (en) * | 2018-10-19 | 2022-11-21 | Сенва Байосайенсиз, Инк. | COMBINATIONS FOR IMMUNOMODULATION IN THE TREATMENT OF CANCER |
CN115480062A (en) * | 2021-06-15 | 2022-12-16 | 广州弘润生物科技有限公司 | Key drug target screening for de-differentiating CD8+ T cells into CD8+ TCM (TCM) and application of key drug target in drugs thereof |
-
2023
- 2023-05-10 CN CN202310520332.1A patent/CN116211860B/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017070137A1 (en) * | 2015-10-20 | 2017-04-27 | Bristol-Myers Squibb Company | Combination of ck2 inhibitors and immune checkpoint modulators for cancer treatment |
CN105560239A (en) * | 2015-12-30 | 2016-05-11 | 耿炜 | Use of CX4945 for preparation of drug having reversal effect on gastric cancer cisplatin-resistant radiation tolerance |
TW201737940A (en) * | 2016-04-08 | 2017-11-01 | 基利科學股份有限公司 | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
CN112789292A (en) * | 2018-07-31 | 2021-05-11 | 皮里斯制药有限公司 | Novel fusion proteins specific for CD137 and PD-L1 |
US20200123153A1 (en) * | 2018-10-19 | 2020-04-23 | Senhwa Biosciences, Inc. | Combinations for immune-modulation in cancer treatment |
CN113015529A (en) * | 2018-10-19 | 2021-06-22 | 生华生物科技股份有限公司 | Immunomodulatory combinations for cancer treatment |
RU2021114145A (en) * | 2018-10-19 | 2022-11-21 | Сенва Байосайенсиз, Инк. | COMBINATIONS FOR IMMUNOMODULATION IN THE TREATMENT OF CANCER |
CN112274642A (en) * | 2020-10-15 | 2021-01-29 | 北京大学人民医院 | Application of CK2 inhibitor in preparation of medicine for treating rheumatoid arthritis |
CN115480062A (en) * | 2021-06-15 | 2022-12-16 | 广州弘润生物科技有限公司 | Key drug target screening for de-differentiating CD8+ T cells into CD8+ TCM (TCM) and application of key drug target in drugs thereof |
CN114617878A (en) * | 2022-05-16 | 2022-06-14 | 深圳大学 | Application of CK2 inhibitor in preparation of anti-aging drugs |
Also Published As
Publication number | Publication date |
---|---|
CN116211860B (en) | 2023-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109294985B (en) | Culture medium system for NK cell in-vitro amplification and NK cell in-vitro amplification method | |
CN107460167B (en) | Method for amplifying NK cells without trophoblasts | |
EP1966369B1 (en) | Method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer | |
CN110520438A (en) | Oncolytic viral therapy | |
JP2021523090A (en) | Methods and compositions for treating tumors | |
CN111918963A (en) | CD3 negative cell population expressing chemokine receptor and cell adhesion molecule and its use and preparation method | |
Nakazawa et al. | Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors | |
JP2010220479A (en) | Method for culturing nk cell and use of the same | |
CN116211860B (en) | Application of CK2 inhibitor CX4945 in preparation of medicines for preventing immune cell depletion in tumor treatment, inhibitor and combination | |
US20190160099A1 (en) | Pharmaceutical composition and use thereof | |
WO2023165573A1 (en) | Culture medium formula for activating whole anti-tumor immune system and method for preparing agonist activated whole immune effector cells | |
CN104906575A (en) | Application of LSECtin as melanoma immunotherapy target | |
CN112831468A (en) | TCM/TSCM cell for improving TIL cell induction and application | |
Gardam et al. | Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma | |
EP1037643A1 (en) | Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy | |
US20210008112A1 (en) | CIML NK cells and Methods Therefor | |
CN108314738B (en) | Bispecific chimeric antigen receptor co-expressing cytokine IL-21, plasmid, CIK cell and MM disease application | |
CN116063556B (en) | IPS-derived CAR-NK cells and their use for the treatment of cancer | |
CN116904400B (en) | Application of calicheamicin in optimization of in-vitro CAR/TCR-T cell product preparation process | |
CN115925974B (en) | Preparation method of universal IPS-derived CAR-NK cells for solid tumors | |
WO2023125696A2 (en) | Activated lymphocyte expansion method having stable and controllable quality, and anti-tumor use thereof | |
EP4052716A1 (en) | Cancer therapy involving car-engineered t-cells and parvovirus h-1 | |
CN109913413B (en) | PD-1 antibody loaded T cell in-vitro culture method, cell preparation and application thereof | |
Tryggestad et al. | Immunogenic properties and antitumor effects of novel therapeutic dendritic cell vaccines expressing hTERT and Survivin antigens in metastatic prostate cancer patients | |
CN114657124A (en) | Preparation method of compound immune cells with high killing capacity on tumor cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 47 Binshui Road, Huanhu West Road, Hexi District, Tianjin City, 300060 Patentee after: TIANJIN CANCER HOSPITAL(TIANJIN MEDICAL University CANCERINSTITUTE& Hospital) Patentee after: Cell Ecology Haihe Laboratory Address before: 2-1-101, Building 1-3, Bolong Industrial Park, north of Yuexin Road and east of Huixin Road, Binhai Science and Technology Park, Binhai High-tech Zone, Binhai New District, Tianjin 300450 Patentee before: Cell Ecology Haihe Laboratory Patentee before: TIANJIN CANCER HOSPITAL(TIANJIN MEDICAL University CANCERINSTITUTE& Hospital) |